miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies

[1]  T. Chambers,et al.  BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells. , 2015, Cancer research.

[2]  H. Schayek,et al.  MiR-377 targets E2F3 and alters the NF-kB signaling pathway through MAP3K7 in malignant melanoma , 2015, Molecular Cancer.

[3]  S. Mazumder,et al.  MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies , 2015, Cell Death and Disease.

[4]  A. Levine,et al.  MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells , 2014, Oncogene.

[5]  Jennifer R. Brown,et al.  A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53 , 2014, British journal of haematology.

[6]  L. Michaux,et al.  14q deletions are associated with trisomy 12, NOTCH1 mutations and unmutated IGHV genes in chronic lymphocytic leukemia and small lymphocytic lymphoma , 2014, Genes, chromosomes & cancer.

[7]  E. Campo,et al.  Recurrent mutations refine prognosis in chronic lymphocytic leukemia , 2014, Leukemia.

[8]  D. Beer,et al.  A MicroRNA Cluster at 14q32 Drives Aggressive Lung Adenocarcinoma , 2014, Clinical Cancer Research.

[9]  Jacek Marzec,et al.  Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukemia. , 2014, Blood.

[10]  K. Garber.  Kinase inhibitors overachieve in CLL , 2014, Nature Reviews Drug Discovery.

[11]  C. Croce,et al.  CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. , 2013, The Journal of clinical investigation.

[12]  S. Tavazoie,et al.  Control of metastatic progression by microRNA regulatory networks , 2013, Nature Cell Biology.

[13]  L. Lam,et al.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.

[14]  R. Dalla-Favera.  Lymphoid malignancies: many tumor types, many altered genes, many therapeutic challenges. , 2012, The Journal of clinical investigation.

[15]  A. Letai,et al.  Targeting the B-cell lymphoma/leukemia 2 family in cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  A. Almasan,et al.  Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells. , 2012, Cancer research.

[17]  Ming You,et al.  MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. , 2012, Carcinogenesis.

[18]  Andrew L. Kung,et al.  Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. , 2012, Cancer cell.

[19]  H. Döhner,et al.  Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Letai,et al.  Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy , 2011, Science.

[21]  J. Maciejewski,et al.  An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. , 2011, Blood.

[22]  Rajesh Singh,et al.  miR 488* inhibits androgen receptor expression in prostate carcinoma cells , 2011, International journal of cancer.

[23]  G. Calin,et al.  MicroRNAs in body fluids—the mix of hormones and biomarkers , 2011, Nature Reviews Clinical Oncology.

[24]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[25]  D. Green,et al.  Mitochondria and cell death: outer membrane permeabilization and beyond , 2010, Nature Reviews Molecular Cell Biology.

[26]  T. Haferlach,et al.  Biological and clinical characterization of recurrent 14q deletions in CLL and other mature B‐cell neoplasms , 2010, British journal of haematology.

[27]  Stefano Amatori,et al.  DNA demethylating antineoplastic strategies: a comparative point of view. , 2010, Genes & cancer.

[28]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[29]  T. Stankovic,et al.  Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. , 2008, Blood.

[30]  Artemis G. Hatzigeorgiou,et al.  Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer , 2008, Proceedings of the National Academy of Sciences.

[31]  A. Letai,et al.  Diagnosing and exploiting cancer's addiction to blocks in apoptosis , 2008, Nature Reviews Cancer.

[32]  A. Letai,et al.  BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. , 2007, Cancer cell.

[33]  A. Lujambio.  CpG Island Hypermethylation of Tumor Suppressor microRNAs in Human Cancer , 2007, Cell cycle.

[34]  M. Caligiuri,et al.  Mcl-1 Is a Relevant Therapeutic Target in Acute and Chronic Lymphoid Malignancies: Down-Regulation Enhances Rituximab-Mediated Apoptosis and Complement-Dependent Cytotoxicity , 2007, Clinical Cancer Research.

[35]  John C Reed,et al.  Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Michael T. Certo,et al.  Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. , 2007, The Journal of clinical investigation.

[37]  J. Byrd,et al.  Narrative Review: Initial Management of Newly Diagnosed, Early-Stage Chronic Lymphocytic Leukemia , 2006, Annals of Internal Medicine.

[38]  C. Croce,et al.  MicroRNA-cancer connection: the beginning of a new tale. , 2006, Cancer research.

[39]  H. Kantarjian,et al.  Variations in the detection of ZAP‐70 in chronic lymphocytic leukemia: Comparison with IgVH mutation analysis , 2006, Cytometry. Part B, Clinical cytometry.

[40]  Yuriy Gusev,et al.  Real-time expression profiling of microRNA precursors in human cancer cell lines , 2005, Nucleic acids research.

[41]  Richard Pazdur,et al.  FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. , 2005, The oncologist.

[42]  Arthur Weiss,et al.  ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. , 2004, The New England journal of medicine.

[43]  N. Agnantis,et al.  Diffuse large B-cell lymphomas with germinal center B-cell-like differentiation immunophenotypic profile are associated with high apoptotic index, high expression of the proapoptotic proteins bax, bak and bid and low expression of the antiapoptotic protein bcl-xl , 2004, Modern Pathology.

[44]  J. Cayuela,et al.  Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma. , 2004, Blood.

[45]  S. Korsmeyer,et al.  BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. , 2001, Molecular cell.

[46]  T. Myers,et al.  An informatics approach identifying markers of chemosensitivity in human cancer cell lines. , 2000, Cancer research.

[47]  Xiao-Rong Zeng,et al.  Regulation of Bcl-xL: a little bit of this and a little bit of STAT , 2000, Current opinion in oncology.

[48]  C. Pepper,et al.  Bcl-2 and bax expression and chlorambucil-induced apoptosis in the T-cells and leukaemic B-cells of untreated B-cell chronic lymphocytic leukaemia patients. , 2000, Leukemia research.

[49]  N. Chiorazzi,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[50]  L. Kanz,et al.  Multimodality treatment including early high-dose chemotherapy with peripheral blood stem cell transplantation in limited-disease small cell lung cancer. , 1998, Seminars in oncology.

[51]  H. Kantarjian,et al.  Prognosis of chronic lymphocytic leukemia: a multivariate regression analysis of 325 untreated patients. , 1987, Blood.

[52]  D. Rossi,et al.  Richter syndrome. , 2013, Advances in experimental medicine and biology.

[53]  L. Lam,et al.  Souers AJ, Leverson JD, Boghaert ER et al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208 , 2013 .

[54]  J. Philippé,et al.  Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. , 2009, Blood reviews.

[55]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.

[56]  B. Cheson,et al.  Chronic lymphocytic leukemia: staging and prognostic factors. , 1998, Seminars in oncology.